Trial Profile
BYLieve:A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant; Goserelin; Letrozole; Leuprorelin
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms BYLieve
- Sponsors Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 Oct 2023 This trial has been completed in Spain according to the European Clinical Trials Database record.
- 08 Sep 2023 This trial has been completed in Denmark, and Netherlands, according to the European Clinical Trials Database record.
- 24 Aug 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.